Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares

Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares

HKPD · NASDAQ · Healthcare / Medical Distribution

1.62USD+0.09 (+5.88%)

Price History

Full chart

Market Stats

Previous Close1.53
Open1.62
Day Range1.53 – 1.63
52-Week Range0.096 – 1.72
Volume7.97K
Market Cap5.95M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.07
Dividend Yield0.00%
50-Day Avg0.3046
200-Day Avg0.5547

About

Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over-the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services. It also offers customs clearance, drugs enlisting, warehouse, and other logistics services. In addition, it provides value-added services such as labeling, extended storage, product inspection, batch processing, and logistics support, as well as sales of health supplements and non-pharmaceutical products. The company serves e-commerce platform logistics partners, merchants, and Chinese e-commerce platforms as well as pharmaceutical distributors. The company was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and changed its name to Cellyan Biotechnology Co., Ltd in December 2025. Cellyan Biotechnology Co., Ltd was incorporated in 2023 and is based in Yau Tong, Hong Kong.

Company Details

  • SectorHealthcare
  • IndustryMedical Distribution
  • CEOMr. Chenyu Liang
  • Employees11
  • HeadquartersWell Town Industrial Building, Yau Tong, Hong Kong, 999077, USA
  • Websitehttps://www.9zt.hk

Leadership

  • Mr. Chenyu LiangCEO & Director · b. 2000
  • Ms. Shu LiuChief Financial Officer · b. 1996
  • Mr. Zifeng WangChief Strategy Officer · b. 1972

Financials

Income Statement

Currency: USD2023-03-312024-03-312025-03-312026-03-31
Total Revenue12.56M16.69M20.31M13.43M
Growth (%)-+32.91%+21.72%-33.87%
Cost of Revenue9.82M13.13M17.90M12.05M
Gross Profit2.74M3.56M2.42M1.39M
Gross Margin21.81%21.32%11.89%10.32%
Operating Expense1.70M1.95M2.28M2.38M
Operating Income1.04M1.61M132.04K-994.90K
Operating Margin8.31%9.64%0.65%-7.41%
EBITDA1.76M2.53M1.21M-918.37K
EBITDA Margin14.01%15.19%5.94%-6.84%
Net Income998.20K1.33M-27.06K-1.14M
Net Income Margin7.95%7.97%-0.13%-8.46%
Interest Expense23.24K82.77K97.67K133.40K
Interest Expense % of Total Revenue0.19%0.50%0.48%0.99%

Balance Sheet

Currency: USD2023-03-312024-03-312025-03-312026-03-31
Total Assets3.41M8.67M9.42M12.84M
Total Liabilities2.82M4.41M4.43M3.26M
Total Equity585.24K4.25M4.99M9.58M
Cash524.61K619.58K748.72K221.84K
Total Debt691.08K2.09M2.37M1.26M
Net Debt166.46K1.47M1.63M1.04M

Cash Flow

Currency: USD2023-03-312024-03-312025-03-312026-03-31
Operating Cash Flow1.73M-394.33K569.21K-751.60K
Investing Cash Flow-132.09K-40.80K-2.45M857.46K
Financing Cash Flow-1.16M537.32K2.00M-630.23K
Capital Expenditure117.70K88.02K154.99K35.47K
Free Cash Flow1.61M-482.35K414.23K-787.07K
FCF to OCF93.18%122.32%72.77%104.72%

Earnings

Report DateMar 28, 2025Aug 14, 2025
EPS Estimate0.000.00
EPS Actual0.08-0.08
Surprise--
Timing--

Key Statistics & Ratios

Market Cap5.95M
Enterprise Value6.84M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.44
Price / Book0.61
EPS-0.07
Book Value0.408
Revenue (TTM)13.43M
Gross Profit (TTM)1.39M
EBITDA-918.37K
Profit Margin-8.46%
Operating Margin-19.32%
Return on Equity-15.59%
Return on Assets-5.64%
Shares Outstanding42.17M
Shares Float15.71M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
0.61%
Insiders
17.00%
Retail / Other
82.39%

Top Institutional Holders

  • StoneX Group Inc
    39.40K0.36%
  • Clear Street Group Inc
    12.02K0.11%
  • UBS Group AG
    1100.00%
  • Two Sigma Investments LLC
    00.00%

Stock Splits

  • Oct 26, 20261:20